Table 2 Number of patients with NAFLD and cholangiocarcinoma in the included case-control studies
Author, year | Number of CCA cases (n) | Number of controls (n) | ||||||
|---|---|---|---|---|---|---|---|---|
iCCA | eCCA | All | ||||||
Total | With NAFLD | Total | With NAFLD | Total | With NAFLD | Total | With NAFLD | |
Welzel et al. 2007 [10] | 535 | 5 (0.9%) | 549 | 4 (7.3%) | 1084 | 9 (0.8%) | 102,782 | 353 (0.34%) |
Zhou et al. 2009 [20] | 317 | 6 (1.9%) | – | – | 317 | 6 (1.9%) | 634 | 8 (1.2%) |
Chang et al. 2013 [17] | 2978 | 156 (5.2%) | 2179 | 89 (4.1%) | 5157 | 245 (4.8%) | 20628a | 410 (2.0%) |
Lee et al. 2015 [18] | – | – | 81 | 17 (21.0%) | 81 | 17 (21.0%) | 162 | 28 (17.3%) |
Kinoshita et al. 2016 [9] | 34 | 15 (44.1%) | – | – | 34 | 15 (44.1%) | 69 | 13 (18.8%) |
Choi et al. 2016 [16] | 1169 | 61 (5.2%) | 1226b | 52 (4.2%) | 2395 | 113 (4.7%) | 4769 | 181 (3.8%) |
Stepien et al. 2016 [19] | 34 | 21 (61.8%) | – | – | 34 | 21 (61.8%) | 67 | 25 (37.3%) |